Cellectis (NASDAQ:CLLS) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS) in a research report report published on Thursday. The firm issued a sell rating on the biotechnology company’s stock.

Separately, Barclays cut their price objective on Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th.

Cellectis Stock Down 7.9 %

Shares of CLLS stock opened at $1.51 on Thursday. The firm’s fifty day moving average price is $1.84 and its two-hundred day moving average price is $2.00. Cellectis has a 1 year low of $1.41 and a 1 year high of $3.38. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $83.93 million, a P/E ratio of -1.16 and a beta of 3.08.

Cellectis (NASDAQ:CLLS) last issued its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.03). The company had revenue of $18.05 million for the quarter, compared to analyst estimates of $5.00 million. Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. During the same period last year, the company posted ($0.31) earnings per share. On average, equities analysts predict that Cellectis will post -0.46 EPS for the current fiscal year.

Institutional Trading of Cellectis

Hedge funds and other institutional investors have recently modified their holdings of the stock. XTX Topco Ltd acquired a new stake in Cellectis during the second quarter worth approximately $29,000. Long Focus Capital Management LLC lifted its holdings in Cellectis by 2.9% during the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after purchasing an additional 130,000 shares during the last quarter. Finally, First Affirmative Financial Network acquired a new stake in Cellectis during the 3rd quarter worth approximately $45,000. Institutional investors own 63.90% of the company’s stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.